Grisell Ortiz‐Lasanta

3.1k total citations
9 papers, 158 citations indexed

About

Grisell Ortiz‐Lasanta is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Grisell Ortiz‐Lasanta has authored 9 papers receiving a total of 158 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 4 papers in Hepatology and 3 papers in Molecular Biology. Recurrent topics in Grisell Ortiz‐Lasanta's work include Liver Disease Diagnosis and Treatment (6 papers), Hepatitis C virus research (4 papers) and Fibroblast Growth Factor Research (2 papers). Grisell Ortiz‐Lasanta is often cited by papers focused on Liver Disease Diagnosis and Treatment (6 papers), Hepatitis C virus research (4 papers) and Fibroblast Growth Factor Research (2 papers). Grisell Ortiz‐Lasanta collaborates with scholars based in United States, Puerto Rico and New Zealand. Grisell Ortiz‐Lasanta's co-authors include Eric Lawitz, Carlos F. Ríos‐Bedoya, M. Rodríguez‐Torres, Leo Tseng, Chaoyin Chen, Hank Mansbach, Rohit Loomba, Linda Morrow, Maya Margalit and Juan P. Frías and has published in prestigious journals such as Journal of Hepatology, Metabolism and Journal of Medical Virology.

In The Last Decade

Grisell Ortiz‐Lasanta

9 papers receiving 151 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Grisell Ortiz‐Lasanta United States 6 106 77 45 45 12 9 158
Samir Rouabhia Algeria 6 121 1.1× 72 0.9× 37 0.8× 46 1.0× 17 1.4× 11 166
Anne Linde Mak Netherlands 8 152 1.4× 82 1.1× 57 1.3× 50 1.1× 32 2.7× 13 210
Felícitas Díaz-Flores Spain 6 82 0.8× 84 1.1× 20 0.4× 18 0.4× 7 0.6× 18 126
Marcela Galoppo Argentina 8 133 1.3× 93 1.2× 20 0.4× 26 0.6× 3 0.3× 9 188
Madison Fairey United Kingdom 3 105 1.0× 28 0.4× 37 0.8× 44 1.0× 32 2.7× 4 147
Anita Arslanow Germany 6 248 2.3× 165 2.1× 16 0.4× 80 1.8× 36 3.0× 16 279
Madhavi Rudraraju United States 5 74 0.7× 38 0.5× 14 0.3× 23 0.5× 7 0.6× 12 100
Jamilya Kaibullayeva Kazakhstan 4 59 0.6× 17 0.2× 15 0.3× 19 0.4× 9 0.8× 9 79
Sulav Shrestha Canada 4 214 2.0× 97 1.3× 28 0.6× 111 2.5× 25 2.1× 8 249
Ingo van Thiel Germany 3 119 1.1× 87 1.1× 5 0.1× 31 0.7× 9 0.8× 7 132

Countries citing papers authored by Grisell Ortiz‐Lasanta

Since Specialization
Citations

This map shows the geographic impact of Grisell Ortiz‐Lasanta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Grisell Ortiz‐Lasanta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Grisell Ortiz‐Lasanta more than expected).

Fields of papers citing papers by Grisell Ortiz‐Lasanta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Grisell Ortiz‐Lasanta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Grisell Ortiz‐Lasanta. The network helps show where Grisell Ortiz‐Lasanta may publish in the future.

Co-authorship network of co-authors of Grisell Ortiz‐Lasanta

This figure shows the co-authorship network connecting the top 25 collaborators of Grisell Ortiz‐Lasanta. A scholar is included among the top collaborators of Grisell Ortiz‐Lasanta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Grisell Ortiz‐Lasanta. Grisell Ortiz‐Lasanta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Harrison, Stephen A., Naim Alkhouri, Grisell Ortiz‐Lasanta, et al.. (2025). A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH. Journal of Hepatology. 83(2). 293–303. 4 indexed citations
2.
Loomba, Rohit, Eric Lawitz, Juan P. Frías, et al.. (2022). Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. ˜The œLancet. Gastroenterology & hepatology. 8(2). 120–132. 72 indexed citations
3.
4.
5.
Lawitz, Eric, Charles Landis, Steven L. Flamm, et al.. (2020). Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. ˜The œLancet. Gastroenterology & hepatology. 5(10). 918–926. 21 indexed citations
6.
7.
Lawitz, Eric, Charles Landis, Benedict Maliakkal, et al.. (2017). Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment.. 66. 13 indexed citations
8.
9.
Rodríguez‐Torres, M., et al.. (2008). Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Annals of Hepatology. 7(1). 72–77. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samir Rouabhia Breakdown of academic impact, for papers by Anne Linde Mak Breakdown of academic impact, for papers by Felícitas Díaz-Flores Breakdown of academic impact, for papers by Marcela Galoppo Breakdown of academic impact, for papers by Madison Fairey Breakdown of academic impact, for papers by Anita Arslanow Breakdown of academic impact, for papers by Madhavi Rudraraju Breakdown of academic impact, for papers by Jamilya Kaibullayeva Breakdown of academic impact, for papers by Sulav Shrestha Breakdown of academic impact, for papers by Ingo van Thiel
Rankless by CCL
2026